| Description | This product is a monoclonal antibody derived from Human (Homo sapiens), which can specifically recognize Transforming growth factor beta 1. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human, Rat, Mouse |
| Isotype | IgG4 |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | ELISA; IHC; Neut; FuncS |
| Application Notes | The antibody is recommended for detection of TGFB1 by IHC, Neut, FuncS assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
Figure 1 Anti-TGFB1 Monoclonal Antibody (V3S-0522-YC2117) in SDS-PAGE
SDS-PAGE analysis of V3S-0522-YC2117 in non-reduced (lane 1) and β-mercaptoethanol-reduced (lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.
Figure 1 Anti-TGFB1 Monoclonal Antibody (V3S-0522-YC2117) in SDS-PAGE
Figure 2 Anti-TGFB1 Monoclonal Antibody (V3S-0522-YC2117) in WB
Western blot analysis of V3S-0522-YC2117 was performed by loading 2 µg onto a 12% Tris-HCl polyacrylamide gel in non-reduced (lane 1) and β-mercaptoethanol-reduced (lane 2) conditions. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with Goat Anti-Human IgG HRP secondary antibody at a dilution of 1:8,000 for 75 minutes. Chemiluminescent detection was performed.
Figure 2 Anti-TGFB1 Monoclonal Antibody (V3S-0522-YC2117) in WB
Figure 3 Anti-TGFB1 Monoclonal Antibody (V3S-0522-YC2117) in SEC-HPLC
The purity of V3S-0522-YC2117 was greater than 95% as determined by SEC-HPLC.
Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl
Figure 3 Anti-TGFB1 Monoclonal Antibody (V3S-0522-YC2117) in SEC-HPLC
Figure 4 Anti-TGFB1 Monoclonal Antibody (V3S-0522-YC2117) in ELISA
ELISA analysis of V3S-0522-YC2117 was performed by coating with recombinant human TGF beta 1 Protein (His-tag) (10804-H08H) (1 μg/mL). Then blocked with BSA and incubated with Anti- Human IL1 Beta Antibody (V3S-0522-YC2117) at a starting concentration of 2 ng/mL. The HRP-conjugated goat anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 4 Anti-TGFB1 Monoclonal Antibody (V3S-0522-YC2117) in ELISA
